Form 4: Castle Biosciences CCO Sells 13,200 Shares

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, sold 13,200 shares of common stock for approximately $37.48 per share, executed under a Rule 10b5-1 plan.

Summary

• Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences Inc. (CSTL), sold 13,200 shares of common stock.
• The transaction occurred on December 11, 2025.
• The shares were sold at a weighted-average price of $37.48 per share, with individual trades ranging from $37.31 to $37.72.
• Following this transaction, Mr. Juvenal directly beneficially owns 86,825 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale reduces direct ownership, the execution under a Rule 10b5-1 plan mitigates the negative signal, suggesting a pre-planned liquidity event rather than a reaction to adverse company news.

Positives

• The sale was conducted under a Rule 10b5-1 plan, which suggests a pre-scheduled transaction rather than a reaction to new, negative information.

Negatives

• An insider sale, even if pre-planned, reduces the officer's direct equity stake in the company.

Industry Context

This is a routine insider transaction for Castle Biosciences. Such transactions, especially when executed under a Rule 10b5-1 plan, are common across industries as executives manage personal finances and diversify portfolios. It does not inherently signal broader industry trends unless a pattern of similar insider activity emerges within the biotech or diagnostics sector.

Related Party Transactions

• Tobin W. Juvenal, Chief Commercial Officer, sold 13,200 shares of common stock of Castle Biosciences Inc. This is a direct transaction between an insider and the market.

Stakeholder Impact

• Shareholders: A reduction in insider ownership could be perceived negatively, though the 10b5-1 plan context lessens this impact. It provides transparency regarding insider trading activities.

Key Dates

Recommendation

The insider sale by the Chief Commercial Officer, while a reduction in direct ownership, was executed under a pre-arranged Rule 10b5-1 plan. This typically indicates a planned liquidity event rather than a signal of deteriorating company fundamentals. Without additional information or a pattern of widespread insider selling, this single transaction does not warrant a change from a 'hold' recommendation.

Keywords

Castle Biosciences, CSTL, Insider Trading, Form 4, Stock Sale, Tobin W. Juvenal, Chief Commercial Officer, 10b5-1 Plan